These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21784829)

  • 1. Association of hemoglobin and survival in peritoneal dialysis patients.
    Molnar MZ; Mehrotra R; Duong U; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1973-81. PubMed ID: 21784829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
    Duong U; Kalantar-Zadeh K; Molnar MZ; Zaritsky JJ; Teitelbaum I; Kovesdy CP; Mehrotra R
    Am J Nephrol; 2012; 35(2):198-208. PubMed ID: 22286821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin variability in patients with chronic kidney disease in the Netherlands.
    van der Putten K; van der Baan FH; Schellekens H; Gaillard CA
    Int J Artif Organs; 2009 Nov; 32(11):787-93. PubMed ID: 20020410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
    Suttorp MM; Hoekstra T; Rotmans JI; Ott I; Mittelman M; Krediet RT; Dekker FW
    BMC Nephrol; 2013 Sep; 14():200. PubMed ID: 24066978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.
    Ryta A; Chmielewski M; Debska-Slizien A; Jagodzinski P; Sikorska-Wisniewska M; Lichodziejewska-Niemierko M
    Int Urol Nephrol; 2017 May; 49(5):903-908. PubMed ID: 28058668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis.
    Dahlinghaus EK; Neu AM; Atkinson MA; Fadrowski JJ
    Pediatr Nephrol; 2014 Dec; 29(12):2387-94. PubMed ID: 25108709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin.
    Avram MM; Blaustein D; Fein PA; Goel N; Chattopadhyay J; Mittman N
    Kidney Int Suppl; 2003 Nov; (87):S6-11. PubMed ID: 14531767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
    Ibrahim HN; Foley RN; Zhang R; Gilbertson DT; Collins AJ
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):623-9. PubMed ID: 19211669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.
    Li S; Foley RN; Collins AJ
    Kidney Int; 2004 May; 65(5):1864-9. PubMed ID: 15086928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
    Thanakitcharu P; Jirajan B
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis.
    Khan I; Krishnan M; Kothawala A; Ashfaq A
    BMC Nephrol; 2011 May; 12():22. PubMed ID: 21595975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus.
    Duong U; Mehrotra R; Molnar MZ; Noori N; Kovesdy CP; Nissenson AR; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2011 May; 6(5):1041-8. PubMed ID: 21511838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.